Elizabeth Croydon

Statistics

Publications

Citations

266

H-Index

Active since

2008

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

European Institute of Oncology

Melanoma Institute Australia

University of Siena

Fondazione IRCCS Istituto Nazionale dei Tumori

Elizabeth Croydon is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, immune checkpoint inhibitors, and melanoma pharmacotherapy.

Publications per year

2008–2021

Publications

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma

Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio et al. · Journal for ImmunoTherapy of Cancer · 2020 · 173 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +11

Study to Determine Adequate Margins in Radiotherapy Planning for Esophageal Carcinoma by Detailing Patterns of Recurrence After Definitive Chemoradiotherapy

M. Button, Carys Morgan, Elizabeth Croydon et al. · International Journal of Radiation Oncology*Biology*Physics · 2008 · 83 citations

Medicine, Oncology, Radiation Oncology +16

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation

Michele Maio, Matteo S. Carlino, Anthony M. Joshua et al. · European Journal of Cancer · 2021 · 10 citations

Medicine, Biomedical Sciences, Oncology +14

1–3 of 3